Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Quizartinib + SGN-CD123A|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Quizartinib||Vanflyta||AC220||FLT3 Inhibitor 64||Vanflyta (quizartinib) is a small molecule that selectively inhibits FLT3, which may induce apoptosis and inhibit tumor growth (PMID: 19654408, PMID: 23497317). Vanflyta (quizartinib) is FDA-approved for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, in patients with newly diagnosed acute myeloid leukemia harboring FLT3 ITD mutations (FDA.gov).|
|SGN-CD123A||SGNCD123A|SGN CD123A||SGN-CD123A is an antibody-drug conjugate comprising a CD123-targeted antibody linked to pyrrolobenzodiazepine dimers, which delivers the DNA cross-linking agent agent to CD123-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 29142066).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|